GLPG

Galapagos NV is a Belgian biotechnology company focused on the discovery and development of novel medicines for inflammatory, fibrotic, and other diseases. The company's research platform combines drug discovery capabilities with clinical development expertise in immunology and inflammation. Galapagos has developed a significant pipeline of wholly-owned and partnered clinical-stage programs targeting conditions including osteoarthritis, idiopathic pulmonary fibrosis, and various inflammatory diseases. The company's most advanced product, Jyseleca (filgotinib), is approved in Europe and Japan for the treatment of rheumatoid arthritis. Galapagos maintains strategic partnerships with major pharmaceutical companies including Gilead Sciences, which holds an equity stake in the company. The company operates research and development facilities in Belgium and the Netherlands with clinical development activities conducted globally.